Linked Life Data

3320184

Source:http://linkedlifedata.com/resource/pubmed/id/3320184

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1988-1-28
pubmed:abstractText
ICI 118551, a selective beta 2 adrenoceptor antagonist, was compared with placebo and propranolol in a double-blind cross-over trial in 11 chronically anxious patients, 8 of whom were continued on benzodiazepines. Each treatment was given for 1 week and there was a significant improvement in anxiety ratings (p less than 0.01) at the end of the 3-week trial. However there was no significant difference between the 3 treatments and no preference by either patients or doctor for any one treatment could be detected. Thus, under the conditions of this study, no beneficial effects of either selective or non-selective beta-blockade on chronic anxiety could be detected. Some previous studies with beta-blockers may have confused an effect on anxiety with an effect on benzodiazepine withdrawal.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0268-1315
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
191-200
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
A double-blind placebo controlled trial of a selective beta 2 adrenoceptor antagonist (ICI 118551) in chronic anxiety.
pubmed:affiliation
Department of Therapeutics and Pharmacology, Queen's University of Belfast, Northern Ireland.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Controlled Clinical Trial